Anavex Life Sciences Corp (AVXL)

[attilathehunt]

Thanks ziggy. You answered my question. It would seem Pfizer would want to preempt others if A2-73 shows promise and now if PLUS is now covered by a patent, I could see a Aricept Plus in the future.

Interesting to note Pfizer's revenue is down appx. 25% from its peak in 2010 (65B to 48B) last year.

Perhaps the wisdom behind chasing the Plus patent is to license it for AD to Pfizer with donezpril and thus limiting off label use for other CNS issues. That would then protect Biogen's MS revenue because Biogen's can combo A2-73 with Tecfidera.

I believe it would be difficult to license A2-73 for one CNS issue if it could be easily be subscribed off label for other CNS issues. Having the Plus patent it looks like we can license AD and MS without the other being at risk for off label. This should maximize licensing agreements with several BP's (in this case with Pfizer and Biogen). Does this should plausible? If so, the Plus patent then becomes even more valuable in my eyes.